Current and historical daily PE Ratio for Astellas Pharma Inc (
) from 2008 to Jun 07 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Astellas Pharma stock (ALPMY) PE ratio as of Jun 07 2024 is 177.72.
More Details
Astellas Pharma Inc (ALPMY) PE Ratio (TTM) Chart
Astellas Pharma Inc (ALPMY) PE Ratio (TTM) Historical Data
View and export this data going back to 2008. Start your Free Trial
Total 1245
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Astellas Pharma PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-07 | 177.7 | 2024-04-04 | 185.6 |
| 2024-06-06 | 178.1 | 2024-04-03 | 187.5 |
| 2024-06-05 | 179.5 | 2024-04-02 | 189.3 |
| 2024-06-04 | 176.5 | 2024-04-01 | 188.9 |
| 2024-06-03 | 173.7 | 2024-03-28 | 188.6 |
| 2024-05-31 | 172.1 | 2024-03-27 | At Loss |
| 2024-05-30 | 170.0 | 2024-03-26 | At Loss |
| 2024-05-29 | 169.3 | 2024-03-25 | At Loss |
| 2024-05-28 | 173.7 | 2024-03-22 | At Loss |
| 2024-05-24 | 175.3 | 2024-03-21 | At Loss |
| 2024-05-23 | 173.0 | 2024-03-20 | At Loss |
| 2024-05-22 | 170.3 | 2024-03-19 | At Loss |
| 2024-05-21 | 168.3 | 2024-03-18 | At Loss |
| 2024-05-20 | 169.1 | 2024-03-15 | At Loss |
| 2024-05-17 | 166.3 | 2024-03-14 | At Loss |
| 2024-05-16 | 169.8 | 2024-03-13 | At Loss |
| 2024-05-15 | 171.9 | 2024-03-12 | At Loss |
| 2024-05-14 | 170.9 | 2024-03-11 | At Loss |
| 2024-05-13 | 168.8 | 2024-03-08 | At Loss |
| 2024-05-10 | 170.5 | 2024-03-07 | At Loss |
| 2024-05-09 | 173.7 | 2024-03-06 | At Loss |
| 2024-05-08 | 174.1 | 2024-03-05 | At Loss |
| 2024-05-07 | 176.3 | 2024-03-04 | At Loss |
| 2024-05-06 | 176.6 | 2024-03-01 | At Loss |
| 2024-05-03 | 176.1 | 2024-02-29 | At Loss |
| 2024-05-02 | 174.9 | 2024-02-28 | At Loss |
| 2024-05-01 | 170.2 | 2024-02-27 | At Loss |
| 2024-04-30 | 167.5 | 2024-02-26 | At Loss |
| 2024-04-29 | 168.9 | 2024-02-23 | At Loss |
| 2024-04-26 | 167.5 | 2024-02-22 | At Loss |
| 2024-04-25 | 167.4 | 2024-02-21 | At Loss |
| 2024-04-24 | 166.1 | 2024-02-20 | At Loss |
| 2024-04-23 | 166.5 | 2024-02-16 | At Loss |
| 2024-04-22 | 167.2 | 2024-02-15 | At Loss |
| 2024-04-19 | 166.7 | 2024-02-14 | At Loss |
| 2024-04-18 | 166.1 | 2024-02-13 | At Loss |
| 2024-04-17 | 166.0 | 2024-02-12 | At Loss |
| 2024-04-16 | 163.9 | 2024-02-09 | At Loss |
| 2024-04-15 | 162.7 | 2024-02-08 | At Loss |
| 2024-04-12 | 167.5 | 2024-02-07 | At Loss |
| 2024-04-11 | 180.5 | 2024-02-06 | At Loss |
| 2024-04-10 | 179.5 | 2024-02-05 | At Loss |
| 2024-04-09 | 183.7 | 2024-02-02 | At Loss |
| 2024-04-08 | 184.6 | 2024-02-01 | At Loss |
| 2024-04-05 | 186.0 | 2024-01-31 | At Loss |
Astellas Pharma Inc (ALPMY) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Astellas Pharma Inc
ISIN : US04623U1025
Share Class Description:
ALPMY: ADRDescription
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers